Early Rheumatoid Arthritis Pts Research Articles

AB0406 Effect of Adalimumab and Impact of Disease Activity and Functional Impairment on Work Instability in Patients with Rheumatoid Arthritis

BackgroundIn patients (pts) with Rheumatoid Arthritis (RA), adalimumab (ADA) plus methotrexate (MTX) treatment is associated with greater improvements in clinical, patient-reported, and work related outcomes compared to MTX monotherapy.ObjectivesTo evaluate...

THU0209 Disease Activity and Structural Damage-Related Differences in Functional Disability in Early and Established Rheumatoid Arthritis

BackgroundA measure of functional impairment, the Health Assessment Questionnaire Disability Index (HAQ), consists of a reversible disease activity-related component (ACT-HAQ) and a joint damage component that increases with time (DAM-HAQ).ObjectivesTo...

FRI0086 Biomarkers identify radiographic progressors and clinical responders among patients with early rheumatoid arthritis

BackgroundBiomarkers that could predict or track disease progression among patients (pts) with rheumatoid arthritis (RA) are of great interest.ObjectivesTo evaluate several biomarkers for association with radiographic and clinical outcomes in...

THU0191 Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone

BackgroundEffective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks of comprehensive disease control (CDC).1ObjectivesThe present...

FRI0089 Assessing maintenance of remission with reduced dose etanercept plus methotrexate, methotrexate alone, or placebo in patients with early rheumatoid arthritis who achieved remission with etanercept and methotrextate: the prize study

BackgroundDuring Phase 1 of the 52 wk open-label PRIZE study treatment of patients (pts) with early (mean 6 mos.) moderate-severe rheumatoid arthritis (RA), who were methotrexate (MTX)/biologic naïve, with 50...

FRI0171 Achieving long-term comprehensive disease control with adalimumab and methotrexate in patients with early rheumatoid arthritis in the optima study

BackgroundThe goals of the treat-to-target strategy for rheumatoid arthritis (RA) are to reduce inflammation, prevent structural damage, and to normalize function.ObjectivesTo compare the percentage of RA patients (pts) achieving comprehensive...